Skip Navigation

Neuro-Oncology 2009 11(2):158-166; doi:10.1215/15228517-2008-072
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hoffmann, J.
Right arrow Articles by Klar, U.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hoffmann, J.
Right arrow Articles by Klar, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2009 by the Society for Neuro-Oncology

Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases

Jens Hoffmann, Iduna Fichtner, Margit Lemm, Philip Lienau, Holger Hess-Stumpp, Andrea Rotgeri, Birte Hofmann and Ulrich Klar

Bayer Schering Pharma AG, TRG Oncology (J.H., P.L., H.H.-S., A.R., B.H., U.K.); Max Delbrück Center for Molecular Medicine (I.F., M.L.); Berlin, Germany

Address correspondence to Jens Hoffmann, Bayer Schering Pharma AG, TRG Oncology, Müllerstrasse 172-178, 13342 Berlin, Germany (jens.hoffmann{at}bayerhealthcare.com).


  Abstract

The aim of this study was to determine the efficacy of sagopilone (ZK-EPO), a novel epothilone, compared with other anticancer agents in orthotopic models of human primary and secondary brain tumors. Autoradiography and pharmacokinetic analyses were performed on rats and mice to determine passage across the blood–brain barrier and organ distribution of sagopilone. Mice bearing intracerebral human tumors (U373 or U87 glioblastoma, MDA-MB-435 melanoma, or patient-derived non-small-cell lung cancer [NSCLC]) were treated with sagopilone 5–10 mg/kg, paclitaxel 8–12.5 mg/kg (or temozolomide, 100 mg/kg) or control (vehicle only). Tumor volume was measured to assess antitumor activity. Sagopilone crossed the blood–brain barrier in both rat and mouse models, leading to therapeutically relevant concentrations in the brain with a long half-life. Sagopilone exhibited significant antitumor activity in both the U373 and U87 models of human glioblastoma, while paclitaxel showed a limited effect in the U373 model. Sagopilone significantly inhibited the growth of tumors from CNS metastasis models (MDA-MB-435 melanoma and patient-derived Lu7187 and Lu7466 NSCLC) implanted in the brains of nude mice, in contrast to paclitaxel or temozolomide. Sagopilone has free access to the brain. Sagopilone demonstrated significant antitumor activity in orthotopic models of both glioblastoma and CNS metastases compared with paclitaxel or temozolomide, underlining the value of further research evaluating sagopilone in the treatment of brain tumors. Sagopilone is currently being investigated in a broad phase II clinical trial program, including patients with glioblastoma, NSCLC, breast cancer, and melanoma.

Keywords: blood–brain barrier, brain tumor models, sagopilone

Received March 13, 2008; Accepted June 23, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.